A phase III randomized study (phase I closed) of radiation therapy and temozolomide versus radiation therapy and nitrosourea [carmustine, lomustine] for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (astrocytoma dominant)

Trial Profile

A phase III randomized study (phase I closed) of radiation therapy and temozolomide versus radiation therapy and nitrosourea [carmustine, lomustine] for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (astrocytoma dominant)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Carmustine (Primary) ; Lomustine (Primary) ; Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Results examining the prognostic value of mutations within IDH1/2, ATRX, CIC, FUBP1, and the TERT promoter in a phase III study of grade III astrocytomas using multivariate analyses presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 11 Dec 2013 Planned end date changed from 1 Apr 2013 to 1 Mar 2020 as reported by ClinicalTrials.gov.
    • 03 Aug 2012 Planned end date 1 Apr 2013 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top